Allergy pill tested to protect heart attack survivors
NCT ID NCT07381803
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study is testing whether fexofenadine, a common allergy medication, can reduce the risk of serious heart and brain events in people who have recently had a heart attack. About 2,800 participants will receive either fexofenadine or a placebo for 24 months. The goal is to see if the drug lowers the chance of death, another heart attack, stroke, or heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fexofenadine hydrochloride (allergy medication)
- What this could lead to
- If it works, this could point toward a simple, low-cost way to reduce the risk of further heart problems after a heart attack.
- What could go wrong
- This is a large phase 3 trial, but fexofenadine is not typically used for heart conditions, so it may not provide any benefit. The study is still recruiting, so results are years away.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Zhejiang University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.